Publication | Closed Access
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).
21
Citations
0
References
2015
Year
UrologyGenitourinary CancerMalignant DiseaseMedicineCancer ManagementAsco Daily NewsFinal TextPathologyClinical OncologyCancer TreatmentProstatic DiseaseOncologyRadiation OncologyAndrogen SuppressionPhase Iii ProtocolCancer ResearchEndocrine-related CancerRtog 0521
LBA5002 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Saturday, May 30, 2015, and in the Annual Meeting Proceedings online supplement to the June 20, 2015, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.